A New York Times report reveals that the COVID-19 pandemic deepened the crisis for patients with rare diseases in Argentina. With over 3 million people affected, only 30% get a definitive diagnosis, and many wait 5 to 10 years. The lack of specialists and disrupted care during the health emergency left thousands without timely treatment.

The Silent Crisis of Rare Diseases in Argentina

In a recent investigation, The New York Times highlighted a pressing health issue affecting millions in Argentina: rare diseases, also known as orphan diseases. These conditions, defined as affecting fewer than 1 in every 2,000 people, often have a genetic origin and are chronic, requiring lifelong management. In Argentina, more than 3 million people live with such diseases, yet the path to diagnosis and treatment remains fraught with obstacles, further compounded by the pandemic.

Worldwide, there are estimated to be between 6,000 and 8,000 distinct rare diseases, many of which are life-threatening or severely debilitating. In Argentina, the National Law 26.689, passed in 2011, guarantees access to diagnosis, treatment, and follow-up care. However, its implementation has been uneven, with significant gaps between regions and between the public and private health sectors.

What the NYT Report Found

The article documents real cases of patients who waited years for a correct diagnosis, the shortage of specialists in the public healthcare system, and how the pandemic disrupted essential treatments. The collapse of healthcare services during the emergency (2020-2021) led to canceled appointments, postponed surgeries, and interruptions in high-cost medication supply, which proved fatal for some patients.

The Pandemic's Impact on Rare Disease Patients

Argentina's healthcare system, already strained, was pushed to its limits during COVID-19. For patients with rare diseases, this meant:

  • Suspension of scheduled consultations and surgical procedures.
  • Inability to access expensive medications and therapies.
  • Delays in diagnostic tests, sometimes leading to irreversible health deterioration.

The report emphasizes that only 30% of patients achieve a definitive diagnosis, with an average wait of 5 to 10 years. The lack of a comprehensive national patient registry and insufficient medical training in rare diseases are cited as major contributors.

Key Data at a Glance

IndicatorData
People affected in ArgentinaMore than 3 million
Identified rare diseases worldwide6,000 - 8,000
Average time to diagnosis5 to 10 years
Patients with accurate diagnosisOnly 30%
Law guaranteeing careLaw 26.689 (2011)

What Patient Organizations Demand

Advocacy groups and medical experts consulted by the NYT agree on urgent needs:

  • Create a national patient registry to track cases and inform policy.
  • Strengthen medical education on rare diseases to speed up recognition.
  • Guarantee coverage of high-cost medications across all provinces.
  • Reduce diagnostic delays through referral networks and telemedicine.

While the challenges are immense, the visibility brought by this international report is a crucial first step. It shines a light on a neglected issue, encouraging dialogue and potential reforms. For the thousands of Argentine families living with rare diseases, hope lies in the growing awareness and the persistent advocacy of patient communities.

Source: The New York Times (August 21, 2026)

Related